NY-ESO-1 is SapVax’s First Target Antigen
SapVax’s lead vaccine, SVX-ESO consists of 3 peptides that cover regions of experimentally proven immunogenic clusters of epitopes of NY-ESO-1, each conjugated to SapVax adjuvants. NY-ESO-1 is a cancer testis antigen (CTA) re-expressed in multiple tumor types and is associated with a more aggressive cancer phenotype. NY-ESO-1 is a well studied and clinically validated tumor antigen.
The target indication for the SVX-ESO vaccine is ovarian cancer. Ovarian cancer is the 5th most common malignancy and a leading cause of cancer mortality in women. In a retrospective analysis of multiple clinical trials in ovarian cancer, vaccination against NY-ESO-1 correlated with an overall 2-year survival advantage compared to patients with NY-ESO-1+ tumors who did not receive vaccination. NY-ESO-1 is expressed on numerous types of tumors including sarcoma, neuroblastoma, myeloma, and bladder cancer, which makes it an attractive immunotherapy for multiple indications.
First-in-human, Phase I studies are planned to assess safety and immunogenicity of SVX-ESO in human volunteers and in ovarian cancer patients with minimal residual disease following first-line tumor debulking and chemotherapy. IND submission is planned for early 2021.